Serious adverse effects · adults with tinnitus
CBT showed no clear difference in serious adverse effects compared with other experimental control (low certainty).
1 finding from 1 review
Depression at end of treatment · adults with tinnitus
1 finding from 1 review
Anxiety · adults with tinnitus
1 finding from 1 review
Serious adverse effects at end of treatment · adults with tinnitus
CBT showed no clear difference in serious adverse effects at end of treatment compared with no intervention/waiting list control (moderate certainty).
1 finding from 1 review
Health‐related quality of life at end of treatment · adults with tinnitus
1 finding from 1 review
Negatively biased interpretations of tinnitus · adults with tinnitus
1 finding from 1 review
Other adverse effects · adults with tinnitus
1 finding from 1 review
Depression at end of treatment · adults with tinnitus
1 finding from 1 review
Anxiety · adults with tinnitus
1 finding from 1 review
Health‐related quality of life · adults with tinnitus
1 finding from 1 review
Negatively biased interpretations of tinnitus · adults with tinnitus
1 finding from 1 review
Other adverse effects · adults with tinnitus
1 finding from 1 review
Outcomes at end of treatment · adults with tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review